biostudies-literatureChelban VMSA CoalitionEuropean Research CouncilFrench Clinical Research ProgrammeMedical Research CouncilHorizon 2020 research and innovation programmeAlzheimer's SocietyPSP AssociationWellcome TrustWellcome Trust equipment and strategic awards4398-4408https://www.ebi.ac.uk/biostudies/studies/S-EPMC9762941biostudies-literatureUnknown145(12)Disease-modifying treatments are currently being trialled in multiple system atrophy. Approaches based solely on clinical measures are challenged by heterogeneity of phenotype and pathogenic complexity. Neurofilament light chain protein has been explored as a reliable biomarker in several neurodegenerative disorders but data on multiple system atrophy have been limited. Therefore, neurofilament light chain is not yet routinely used as an outcome measure in multiple system atrophy. We aimed to comprehensively investigate the role and dynamics of neurofilament light chain in multiple system atrophy combined with cross-sectional and longitudinal clinical and imaging scales and for subject trial selection. In this cohort study, we recruited cross-sectional and longitudinal cases in a multicentBrain : a journal of neurologyNeurofilament light levels predict clinical progression and death in multiple system atrophy.PMC9762941WT104033/Z/14/Z720931004681712517220258WT093205MAJabbari EFoubert-Samier AGuo TGonzalez MNg BLZetterberg HChelban VWellington HBocchetta MSynofzik MFoltynie TLeigh PNHoulden HTodd EGRohrer JDBurn DJSegura BCompta YWilke CMarti MJChurch ASchols LPavese NMorris HRLe Traon APVijiaratnam NNikram ETariq AKobylecki CMassey LHu MTMAlikhwan SPainous CSenkevich KJunque CPeran PMunoz EOlufodun SPerez-Soriano AMeissner WGRowe JBHeslegrave AJRascol OPchelina SCostantini AAJaunmuktane ZZhelcheska KLaurens BWood NfalseNeurofilament light levels predict clinical progression and death in multiple system atrophy.Disease-modifying treatments are currently being trialled in multiple system atrophy. Approaches based solely on clinical measures are challenged by heterogeneity of phenotype and pathogenic complexity. Neurofilament light chain protein has been explored as a reliable biomarker in several neurodegenerative disorders but data on multiple system atrophy have been limited. Therefore, neurofilament light chain is not yet routinely used as an outcome measure in multiple system atrophy. We aimed to comprehensively investigate the role and dynamics of neurofilament light chain in multiple system atrophy combined with cross-sectional and longitudinal clinical and imaging scales and for subject trial selection. In this cohort study, we recruited cross-sectional and longitudinal cases in a multicent2022-01-01T00:00:00Z2022 Dec2025-04-18T15:21:16.999Z2025-04-07T02:00:09.482ZS-EPMC97629413590301710.1093/brain/awac253